Naringin inhibits ovarian tumor growth by promoting apoptosis: An in vivo study

Cai,Liping; Wu,Heli; Tu,Chunhua; Wen,Xiaochun; Zhou,Bei

doi:10.3892/ol.2018.8611

Naringin inhibits ovarian tumor growth by promoting apoptosis: An in vivo study

Authors:
- Liping Cai
- Heli Wu
- Chunhua Tu
- Xiaochun Wen
- Bei Zhou
View Affiliations

Affiliations: Department of Obstetrics and Gynecology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330006, P.R. China, Graduate School, Nanchang University, Nanchang, Jiangxi 330006, P.R. China
Published online on: May 2, 2018 https://doi.org/10.3892/ol.2018.8611
Pages: 59-64
Copyright: © Cai et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the antitumor activities of naringin in ovarian cancer, and to assess the underlying mechanisms. Ovarian tumor cells were implanted into nude mice to produce ovarian tumors in vivo. The mice were divided into six groups: Control, low dose naringin [0.5 mg/kg, intraperitoneal (i.p.)], middle dose naringin (1 mg/kg, i.p.), high dose naringin (2 mg/kg, i.p.), positive control (cisplatin, 2 mg/kg, i.p.) and a combination of cisplatin and naringin (both 2 mg/kg). Following administration of naringin and/or cisplatin, the tumor size and weight were measured. Apoptosis of tumor cells was detected using a terminal deoxynucleotidyl transferase dUTP nick end labeling assay. Apoptosis‑associated gene expression was detected using reverse transcription‑polymerase chain reaction and immunohistochemistry. In the range of 0.5‑2 mg/kg, naringin dose‑dependently inhibited tumor growth, as demonstrated by a decrease in tumor size and weight. Naringin promoted apoptosis of the ovarian tumor cells. Additionally, naringin reduced the expression of B‑cell lymphoma (Bcl)‑2, Bcl‑extra large (Bcl‑xL), cyclin D1, c‑Myc and survivin, while it increased the expression of caspase‑3 and caspase‑7. The data demonstrated that naringin inhibited ovarian tumor growth in vivo. Its mechanisms may be associated with caspase‑7‑, caspase‑3‑, Bcl‑2‑ and Bcl‑xL‑mediated apoptosis. Nevertheless, the clinical application of naringin in the treatment of ovarian cancer requires further study.

View Figures

View References

1	Viau M, Renaud MC, Gregoire J, Sebastianelli A and Plante M: Paraneoplastic syndromes associated with gynecological cancers: A systematic review. Gynecol Oncol. 146:661–671. 2017. View Article : Google Scholar : PubMed/NCBI
2	Banach P, Suchy W, Dereziński P, Matysiak J, Kokot ZJ and Nowak-Markwitz E: Mass spectrometry as a tool for biomarkers searching in gynecological oncology. Biomed Pharmacother. 92:836–842. 2017. View Article : Google Scholar : PubMed/NCBI
3	Jelovac D and Armstrong DK: Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 61:183–203. 2011. View Article : Google Scholar : PubMed/NCBI
4	Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL and Burger RA: Gynecologic Oncology Group: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 354:34–43. 2006. View Article : Google Scholar : PubMed/NCBI
5	Zhou YF: High intensity focused ultrasound in clinical tumor ablation. World J Clin Oncol. 2:8–27. 2011. View Article : Google Scholar : PubMed/NCBI
6	To SKY, Mak ASC, Fung Eva YM, Che CM, Li SS, Deng W, Ru B, Zhang J and Wong AST: β-catenin downregulates Dicer to promote ovarian cancer metastasis. Oncogene. 36:5927–5938. 2017. View Article : Google Scholar : PubMed/NCBI
7	Mihanfar A, Fattahi A and Nejabati HR: MicroRNA-mediated drug resistance in ovarian cancer. J Cell Physiol. Jun 19–2017.(Epub ahead of print). View Article : Google Scholar : PubMed/NCBI
8	Kuo YT, Chang TT, Muo CH, Wu MY, Sun MF, Yeh CC and Yen HR: Use of complementary traditional chinese medicines by adult cancer patients in Taiwan: A nationwide population-based study. Integr Cancer Ther. June 1–2017.(Epub ahead of print).
9	Singh N, Bansal Y, Bhandari R, Marwaha L, Singh R, Chopra K and Kuhad A: Naringin reverses neurobehavioral and biochemical alterations in intracerebroventricular collagenase-induced intracerebral hemorrhage in rats. Pharmacology. 100:172–187. 2017. View Article : Google Scholar : PubMed/NCBI
10	Chen R, Qi QL, Wang MT and Li QY: Therapeutic potential of naringin: An overview. Pharm Biol. 54:3203–3210. 2016. View Article : Google Scholar : PubMed/NCBI
11	Jeon SM, Bok SH, Jang MK, Kim YH, Nam KT, Jeong TS, Park YB and Choi MS: Comparison of antioxidant effects of naringin and probucol in cholesterol-fed rabbits. Clin Chim Acta. 317:181–190. 2002. View Article : Google Scholar : PubMed/NCBI
12	Jagetia GC and Reddy TK: Modulation of radiation-induced alteration in the antioxidant status of mice by naringin. Life Sci. 77:780–794. 2005. View Article : Google Scholar : PubMed/NCBI
13	Rajadurai M and Stanely Mainzen Prince P: Preventive effect of naringin on lipid peroxides and antioxidants in isoproterenol-induced cardiotoxicity in Wistar rats: Biochemical and histopathological evidences. Toxicology. 228:259–268. 2006. View Article : Google Scholar : PubMed/NCBI
14	Li W, Wang C, Peng J, Liang J, Jin Y, Liu Q, Meng Q, Liu K and Sun H: Naringin inhibits TNF-α induced oxidative stress and inflammatory response in HUVECs via Nox4/NF-κB and PI3K/Akt pathways. Curr Pharm Biotechnol. 15:1173–1182. 2014. View Article : Google Scholar : PubMed/NCBI
15	Ramalingayya GV, Nampoothiri M, Nayak PG, Kishore A, Shenoy RR, Rao Mallikarjuna C and Nandakumar K: Naringin and rutin alleviates episodic memory deficits in two differentially challenged object recognition tasks. Pharmacogn Mag. 12 Suppl 1:S63–S70. 2016. View Article : Google Scholar : PubMed/NCBI
16	Cao X, Lin W, Liang C, Zhang D, Yang F, Zhang Y, Zhang X, Feng J and Chen C: Naringin rescued the TNF-α-induced inhibition of osteogenesis of bone marrow-derived mesenchymal stem cells by depressing the activation of NF-κB signaling pathway. Immunol Res. 62:357–367. 2015. View Article : Google Scholar : PubMed/NCBI
17	Chang HY and Yang X: Proteases for cell suicide: Functions and regulation of caspases. Microbiol Mol Biol Rev. 64:821–846. 2000. View Article : Google Scholar : PubMed/NCBI
18	Zhu G, Wang X, Wu S and Li Q: Involvement of activation of PI3K/Akt pathway in the protective effects of puerarin against MPP+-induced human neuroblastoma SH-SY5Y cell death. Neurochem Int. 60:400–408. 2012. View Article : Google Scholar : PubMed/NCBI
19	Linder M and Tschernig T: Vasculogenic mimicry: Possible role of effector caspase-3, caspase-6 and caspase-7. Ann Anat. 204:114–117. 2016. View Article : Google Scholar : PubMed/NCBI
20	Médoc M, Dhilly M, Matesic L, Toutain J, Krause-Heuer AM, Delamare J, Fraser BH, Touzani O, Barré L, Greguric I and Sobrio F: In vivo evaluation of radiofluorinated caspase-3/7 inhibitors as radiotracers for apoptosis imaging and comparison with [18F]ML-10 in a stroke model in the rat. Mol Imaging Biol. 18:117–126. 2016. View Article : Google Scholar : PubMed/NCBI
21	Zolota V, Gerokosta A, Melachrinou M, Kominea A, Aletra C and Scopa CD: Microvessel density, proliferating activity, p53 and bcl-2 expression in in situ ductal carcinoma of the breast. Anticancer Res. 19:3269–3274. 1999.PubMed/NCBI
22	Takehara T, Liu X, Fujimoto J, Friedman SL and Takahashi H: Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology. 34:55–61. 2001. View Article : Google Scholar : PubMed/NCBI
23	Li Z, Cui J, Yu Q, Wu X, Pan A and Li L: Evaluation of CCND1 amplification and CyclinD1 expression: Diffuse and strong staining of CyclinD1 could have same predictive roles as CCND1 amplification in ER positive breast cancers. Am J Transl Res. 8:142–153. 2016.PubMed/NCBI
24	Yamamoto K, Lee BJ, Li C, Dubois RL, Hobeika E, Bhagat G and Zha S: Early B-cell-specific inactivation of ATM synergizes with ectopic CyclinD1 expression to promote pre-germinal center B-cell lymphomas in mice. Leukemia. 29:1414–1424. 2015. View Article : Google Scholar : PubMed/NCBI
25	Kandela I, Jin HY and Owen K: Reproducibility Project: Cancer biology: Registered report: BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Elife. 4:e070722015. View Article : Google Scholar : PubMed/NCBI
26	Lin CY, Lovén J, Rahl PB, Paranal RM, Burge CB, Bradner JE, Lee TI and Young RA: Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 151:56–67. 2012. View Article : Google Scholar : PubMed/NCBI
27	Zhang E, Li W, Yin D, De W, Zhu L, Sun S and Han L: c-Myc-regulated long non-coding RNA H19 indicates a poor prognosis and affects cell proliferation in non-small-cell lung cancer. Tumour Biol. 37:4007–4015. 2016. View Article : Google Scholar : PubMed/NCBI
28	Wu DW, Hsu NY, Wang YC, Lee MC, Cheng YW, Chen CY and Lee H: c-Myc suppresses microRNA-29b to promote tumor aggressiveness and poor outcomes in non-small cell lung cancer by targeting FHIT. Oncogene. 34:2072–2082. 2015. View Article : Google Scholar : PubMed/NCBI
29	Xia B, Tian C, Guo S, Zhang L, Zhao D, Qu F, Zhao W, Wang Y, Wu X, Da W, et al: c-Myc plays part in drug resistance mediated by bone marrow stromal cells in acute myeloid leukemia. Leuk Res. 39:92–99. 2015. View Article : Google Scholar : PubMed/NCBI
30	Kato J, Kuwabara Y, Mitani M, Shinoda N, Sato A, Toyama T, Mitsui A, Nishiwaki T, Moriyama S, Kudo J and Fujii Y: Expression of survivin in esophageal cancer: Correlation with the prognosis and response to chemotherapy. Int J Cancer. 95:92–95. 2001. View Article : Google Scholar : PubMed/NCBI
31	Mitrović Z, Ilić I, Aurer I, Kinda SB, Radman I, Dotlić S, Ajduković R and Labar B: Prognostic significance of survivin and caspase-3 immunohistochemical expression in patients with diffuse large B-cell lymphoma treated with rituximab and CHOP. Pathol Oncol Res. 17:243–247. 2011. View Article : Google Scholar : PubMed/NCBI